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Abstract
Background: Persistent symptoms attributed to Lyme borreliosis often include self-reported cognitive impairment.
However, it remains unclear whether these symptoms can be substantiated by objective cognitive testing.
Methods: For this observational study, cognitive performance was assessed in 280 adults with persistent symptoms
attributed to Lyme borreliosis (as part of baseline data collected for the Dutch PLEASE study). Cognitive testing
covered the five major domains: episodic memory, working memory / attention, verbal fluency, information-
processing speed and executive function. Patients’ profiles of test scores were compared to a large age-, education-
and sex-adjusted normative sample using multivariate normative comparison. Performance validity was assessed to
detect suboptimal effort, and questionnaires were administered to measure self-reported cognitive complaints,
fatigue, anxiety, depressive symptoms and several other psychological factors.
Results: Of 280 patients, one was excluded as the test battery could not be completed. Of the remaining 279
patients, 239 (85.4%) displayed sufficient performance validity. Patients with insufficient performance validity felt
significantly more helpless and physically fatigued, and less orientated. Furthermore, they had a lower education
level and less often paid work. Of the total study cohort 5.7% (n = 16) performed in the impaired range. Among the
239 patients who displayed sufficient performance validity, 2.9% (n = 7) were classified as cognitively impaired. No
association between subjective cognitive symptoms and objective impairment was found.
Conclusions: Only a small percentage of patients with borreliosis-attributed persistent symptoms have objective
cognitive impairment. Performance validity should be taken into account in neuropsychological examinations of
these patients. Self-report questionnaires are insufficiently valid to diagnose cognitive impairment.
Trial registration: ClinicalTrials.gov NCT01207739. Registered 23 September 2010.
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Background
Patients with persistent symptoms attributed to Lyme
borreliosis often report a variety of cognitive symptoms.
However, subjective cognitive symptoms are not always
due to underlying cognitive impairments. Previously,
subjective ratings of memory capabilities and objective
memory performance were only weakly correlated in
patients with post-treatment Lyme disease [1]. Most pre-
vious studies that compared cognitive performance of
Lyme patients to performance of healthy controls found
a worse performance in Lyme patients at group level [2–
12]. The most affected cognitive domain was episodic
memory. Findings concerning the domains verbal flu-
ency and processing speed were less consistent. How-
ever, most studies were relatively small (n < 80),
originated from the US, and used diverse inclusion cri-
teria and methods. In the 4 larger US studies, mild to no
cognitive abnormalities were identified [1, 2, 12, 13]. As
both the Borrelia species and the clinical presentation of
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Lyme disease in Europe and the US differ [14], cognitive
function in European Lyme patients requires separate
assessment. Furthermore, most previous studies have
not taken performance validity into account. This is cru-
cial, as a suboptimal performance results in poor tests
scores not reflecting an individual’s actual cognitive sta-
tus. Very recently, the study by Touradji et al. in a group
of US patients with post-treatment Lyme disease showed
that 24% of the sample displayed suboptimal effort on
measures of performance validity [12]. Hence, subopti-
mal performance affects the validity and reliability of
neuropsychological outcomes, resulting in false positive
results (i.e., patients incorrectly labelled as having a cog-
nitive impairment) [15]. This stresses the need to take
performance validity testing into account when cogni-
tively assessing patients with persistent symptoms attrib-
uted to Lyme disease.
The aim of the present study was to objectively assess
cognitive performance using sensitive tests in a large co-
hort of patients with persistent symptoms attributed to
Lyme borreliosis, while taking performance validity into
account, and to compare cognitive performance out-
comes with subjective symptoms.
Methods
The current study uses baseline data collected between
2010 and 2013 as part of the Persistent Lyme Empiric
Antibiotic Study Europe (PLEASE). Previously, we re-
ported the primary and secondary outcome measures of
this multicenter, placebo-controlled, double-blind ran-
domized controlled trial from the Netherlands (Clinical-
Trials.gov NCT01207739) [16, 17]. The local Institutional
Review Board approved the PLEASE protocol, and in-
formed consent was obtained from each participant. Here
we provide a detailed report of the baseline cognitive and
self-report questionnaire data. The study population com-
prises adult patients (n = 280) referred with persistent
symptoms attributed to Lyme borreliosis, preceded by
confirmed symptomatic Lyme disease or accompanied by
positive B. burgdorferi IgG or IgM antibodies, as con-
firmed by means of immunoblot assay. Patients were not
required to have received antibiotic treatment before
study entry. Major symptoms included musculoskeletal
pain, cognitive disturbances and/or fatigue. Details about
inclusion and exclusion criteria have been published previ-
ously [16].
Outcomes
Cognitive performance was assessed using an extensive
neuropsychological test battery covering five major cog-
nitive domains: episodic memory, working memory / at-
tention, verbal fluency, information-processing speed
and executive function. Episodic memory was assessed
using the Rey Auditory Verbal Learning Test (RAVLT),
working memory / attention with the Digit Span, verbal
fluency with the Category Fluency Test (animal/profes-
sion naming), and information-processing speed with
the Trail Making Test Part A and the mean response
time of cards I and II from the Stroop Color-Word Test,
and the Symbol-Digit Substitution Test. Executive func-
tion was measured using the Interference Score of the
Trail Making Test (Part B/Part A) and the Stroop Inter-
ference Score (card III/mean of cards I and II). Assess-
ment details have been published previously [17].
To identify participants with insufficient performance
validity, the Amsterdam Short Term Memory test
(ASTM) was administered [18]. A poor performance on
this task indicates suboptimal mental effort. The recom-
mended cut-off score is 85 (maximum score = 90), with
86% sensitivity and 87% specificity [19]. However, since
our goal was to prioritize optimal specificity (> 90%),
adopting a conservative approach that reduces the risk
of false alarms on performance validity tests (i.e., incor-
rectly labelling a participant as someone displaying sub-
optimal effort), we used a cut-off score of < 83 (which
has a specificity of 95% and a sensitivity of 76%).
Subjective measurement of cognitive function was
assessed with the Cognitive Failures Questionnaire (CFQ)
[20], fatigue by the Checklist Individual Strength (CIS)
[16], anxiety and depressive symptoms by the Hospital
Anxiety and Depression Scale (HADS) [21], self-efficacy
by a modified version of the Arthritis Self-Efficacy Scale
(i.e., ‘pain’ replaced by ‘physical symptoms’) [22], illness
cognitions by the Illness Cognition Questionnaire (ICQ)
[23], worrying by the Penn-State Worry Questionnaire
(PSWQ) [24], neuroticism and extraversion by the
Eysenck Personality Questionnaire (EPQ) [25], and fear of
body sensations by the Body Sensations Questionnaire
(BSQ) [26].
Statistical analysis
First, we investigated which demographic/psychological
factors were associated with poor performance validity.
For patients with sufficient performance validity, we
determined whether their cognitive performance was im-
paired by comparing individual test performances to an
extensive normative sample (n = 26,939) from the Ad-
vanced Neuropsychological Diagnostics Infrastructure
(ANDI) [27]. We performed a multivariate normative
comparison (MNC) on each patient’s neuropsychological
test profile, applying corrections for age, sex and educa-
tion level. The MNC provides an individual classification
based on the profile of tests as either ‘cognitively im-
paired’ or ‘cognitively unimpaired’ [27].
We explored performance on individual cognitive
domains, averaging age-, sex- and education-adjusted z-
scores per domain. A domain was classified as ‘impaired’
if z < − 1.5 (i.e., more than 1.5 SD below the normative
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mean). The relation between objective cognitive func-
tioning and subjective complaints was analyzed with
Pearson correlation coefficients.
Alpha was set at 0.05 throughout (two-tailed), and
95% confidence intervals are reported when appropriate.
Benjamini-Hochberg correction was used to reduce the
false discovery rate for multiple comparisons, accepting
a false discovery rate of 0.10.
Results
Of the 280 patients included, one was unable to perform
several neuropsychological tests due to visual impair-
ment unrelated to Lyme disease. Of the 279 patients
fully examined, 239 (85.4%) displayed sufficient perform-
ance validity.
Table 1 shows patient characteristics stratified by per-
formance validity status.
Patients with insufficient performance validity had sig-
nificantly lower education levels and less often paid
work. They also reported significantly more feelings of
helplessness (ICQ subscale helplessness, F(1,275) = 9.77),
experienced more physical fatigue (CIS Activity subscale,
F(1,276) = 6.79), and reported more problems in daily
orientation (CFQ Orientation subscale, F(1,276) = 8.40).
Compared to the normative sample, 2.9% of patients
(7/239) were cognitively impaired. For the separate do-
mains, 2.1% were impaired on episodic memory (5/239),
5.4% on working memory / attention (13/239), 0.8% on
verbal fluency (2/239), 2.1% on information-processing
speed (5/239), and 0.4% on executive function (1/239).
Table 2 shows the raw neuropsychological test scores as
well as mean z-scores, and percentage of individuals
with a cognitive decrement (z-score < 1.0 SD below the
age, sex and education-adjusted normative mean).
No significant correlation between overall cognitive
performance and subjective cognitive complaints (CFQ
total score) was found in patients with sufficient per-
formance validity (r = 0.120, p = 0.064). A significant
correlation was found between objective performance
and problems in orientation (CFQ subscale orientation;
r = 0.246 (p < 0.001). Performance and other CFQ sub-
scales did not show any correlations (p = 0.10–0.98).
Discussion
We have assessed neurocognitive function in the largest
sample of patients with persistent symptoms attributed
to Lyme disease so far, using sensitive tests and exten-
sive normative data. Furthermore, this study was the first
European study to take performance validity into ac-
count. In our study, 15% of patients displayed insuffi-
cient performance validity using a conservative cut-off
that prioritizes specificity over sensitivity (i.e., reducing
the chance of incorrectly labelling an individuals as dis-
playing poor performance validity), indicating that their
neuropsychological test scores cannot be interpreted reli-
ably as they might not reflect the patients’ actual cogni-
tive abilities. Of note, there remains a possibility that
this group with insufficient performance validity con-
tains legitimate poor performers. For example, they may
have been too fatigued to perform sufficiently. Our per-
centage of insufficient performance is considerably lower
than in the study of Touradji et al. [12] who found that
24% of their sample of post-treatment Lyme disease pa-
tients showed suboptimal effort, which may have been
due to our conservative approach in assessing subopti-
mal effort. These substantial proportions of patients dis-
playing suboptimal effort, however, illustrate the need
for performance validity testing when assessing cogni-
tion in patients with persistent neuropsychological
symptoms [15]. Patients who displayed insufficient effort
reported more fatigue, memory-orientation difficulties,
and more feelings of helplessness than the optimal per-
formers. Additionally, these patients were more often
without paid work and had lower education levels. It
should also be noted that only 22.5% (9/40) of the indi-
viduals who displayed suboptimal effort would have been
classified as ‘cognitively impaired’ based on the perform-
ance on all other neuropsychological tests. After exclu-
sion of patients with poor performance validity, only
2.9% had impaired cognitive function. This rate is low
compared to the high level of cognitive complaints re-
ported by patients (on average about 1 SD above the
normative mean on the CFQ) [20]. The lack of correl-
ation between objective and subjective cognitive func-
tioning, was also reported in another large study in
patients with Lyme-associated symptoms [1]. This lack
of correlation between objective cognitive performance
and subjective cognitive complaints is not specific for
Lyme, but has been demonstrated in other disorders as
well (including HIV, dementia, and rheumatoid arthritis)
[28–30]. Subjective cognitive complaints are often asso-
ciated with depressive symptoms [29]. The percentage of
2.9% cognitively impaired patients is comparable to what
is found in the normal population (i.e., by definition
2.3% of a normative sample performs worse than 2 SD
below the normative mean). Similar to our results, the
study by Kaplan et al. [1] found only a small percentage
of cognitively impaired individuals. That study also ex-
amined personality characteristics, albeit with a smaller
sample size and a less extensive test battery than the
present study. Another large study did not find any dif-
ferences between patients and healthy controls in cogni-
tive function either [2]. However, a very recent large
study, which did take performance validity into account,
found a much higher percentage [12]. Furthermore, two
studies by Keilp et al. found distinctive cognitive differ-
ence between patients with symptoms attributed to
Lyme disease and healthy controls [6, 7]. We can only
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speculate on an explanation for the difference in impair-
ment for the patients with sufficient performance. Pos-
sibly, differences between Borrelia species in the US and
Europe may play a role. In addition, differences in
recruitment bias across the various studies may also
have played a role. For instance, in the paper by Touradji
et al. [12] it is stated that participants partially were self-
referred, whereas our patients were all referred to the
Table 1 Demographic and psychosocial factors stratified by performance validitya
Characteristic Good performance
validity (n = 239)
Poor performance
validity (n = 40)
P Value
Women, no. (%) 109 (45.6) 19 (47.5) 0.82
Education level, no. (%)
Low (≤8 years) 1 (0.4) 0 (0) 0.03
Average (9–11 years) 125 (52.7) 28 (71.8)
High (≥12 years) 111 (46.8) 11 (28.2)
Paid work, no. (%) 154 (64.7) 17 (43.6) 0.01
Age, mean (± SD), years 48.7 (11.9) 49.0 (11.9) 0.87
Duration of symptoms, median (IQR), years 2.7 (1.3–6.3) 1.8 (0.7–5.7) 0.13
Previous antibiotic treatment for Lyme disease, no. (%) 213 (89,1) 33 (82.5) 0.23
Delay symptom onset and treatment, median (IQR), weeks 22.5 (3.0–103.5) 15.5 (2.0–69.0) 0.41
History of meningoradiculitis (neuroborreliosis), no. (%)c 18 (7.5) 3 (7.7) 0.97
CFQ, mean (95% CI)
Orientation 3.92 (3.65–4.18) 4.98 (4.20–5.75) 0.004b
Distractibility 11.29 (10.71–11.87) 12.98 (11.58–14.37) 0.03
Blunders 7.04 (6.70–7.38) 7.95 (7.15–8.75) 0.05
Memory 7.32 (7.05–7.59) 7.03 (6.28–7.77) 0.43
Total 43.23 (41.52–44.94) 47.73 (43.24–52.21) 0.05
HADS, mean (95% CI)
Anxiety 6.36 (5.82–6.90) 6.08 (4.90–7.26) 0.71
Depression 7.47 (6.98–7.96) 8.76 (7.33–10.19) 0.06
CIS, mean (95% CI)
Fatigue severity 43.62 (42.33–44.91) 47.25 (44.38–50.11) 0.03
Concentration 23.84 (22.92–24.76) 25.35 (22.74–27.96) 0.23
Motivation 16.67 (15.92–17.42) 17.93 (15.93–19.92) 0.22
Activity 13.92 (13.27–14.57) 16.15 (14.73–17.57) 0.01b
Total 98.03 (95.34–100.72) 106.65 (100.82–112.49) 0.02
Self-efficacy, mean (95% CI) 17.28 (16.60–17.96) 15.62 (13.92–17.31) 0.07
ICQ, mean (95% CI)
Helplessness 13.26 (12.71–13.80) 15.54 (14.20–16.87) 0.002b
Acceptance 13.68 (13.17–14.20) 13.42 (12.27–14.58) 0.70
Perceived benefits 11.35 (10.82–11.88) 12.63 (11.43–13.82) 0.07
EPQ, mean (95% CI)
Neuroticism 8.27 (7.59–8.96) 7.67 (6.22–9.12) 0.50
Extraversion 11.44 (10.83–12.04) 12.21 (10.60–13.81) 0.34
PSWQ, mean (95% CI) 42.17 (40.55–43.78) 42.15 (38.30–46.00) 0.99
BSQ, mean (95% CI) 2.27 (2.19–2.35) 2.38 (2.17–2.59) 0.33
Abbreviations: BSQ body sensations questionnaire, CFQ Dutch version of the Cognitive Failures Questionnaire, CIS checklist individual strength, EPQ Eysenck
Personality Questionnaire, HADS hospital anxiety and depression scale, ICQ illness cognition questionnaire, PSWQ Penn-State Worry Questionnaire
aBetween-group differences in characteristics were analyzed with analysis of variance for continuous variables, chi-square tests for proportions, and Kruskal-Wallis
tests for ordinal variables and data that were not normally distributed
bSignificant with the Benjamini-Hochberg correction, accepting a false discovery rate of 0.10
cDiagnosis by intrathecal Borrelia antibody production
Berende et al. BMC Infectious Diseases          (2019) 19:833 Page 4 of 6
study centers by a primary care physician or medical
specialty.
In addition to the low prevalence of cognitive impair-
ments in our study, the pathogenesis of impaired cogni-
tion in relation to Lyme disease is still unclear, with
scarce evidence for underlying central nervous system
pathology [31].
A potential limitation of the present study is the ab-
sence of a contemporaneous control group of healthy
individuals. However, we compared the individuals’ per-
formances to a substantially larger normative sample,
with specific adjustments for age, education and sex,
than would have been ever possible with recruiting our
own controls. Additionally, the fact that our study popu-
lation was more heterogenous than previous studies
could be seen as a limitation, and not all patients re-
ceived previous treatment with antibiotics.
Conclusions
The present study, taking performance validity into ac-
count in a large, well-defined cohort of patients with
persistent symptoms attributed to Lyme borreliosis,
demonstrates that only a small percentage of patients
can be classified as cognitively impaired. Furthermore,
self-reported symptoms of cognitive problems are unre-
lated to performance on neuropsychological tests in pa-
tients with Lyme-associated symptoms.
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Table 2 Neuropsychological test scores per domain and per testa
Good performance validity (n = 239) Poor performance validity (n = 40)
mean raw
score (SD)
mean
z-score (SD)
cognitive decrement
no. (%)
mean raw score
(SD)
mean z-score
(SD)
cognitive decrement
no. (%)
Episodic memory − 0.12 (0.71) − 0.40 (0.81)
RAVLT (immediate recall,
total of trials 1–5)
45.3 (8.4) −0.12 (0.71) 29 (12.1) 41.0 (8.5) −0.43 (0.75) 8 (20.0)
RAVLT (delayed recall) 9.4 (2.8) −0.11 (0.80) 30 (12.6) 8.4 (3.3) −0.37 (1.01) 9 (22.5)
Working memory / attention 0.11 (1.01) −0.40 (0.86)
Digit Span 15.4 (3.3) 0.11 (1.01) 31 (13.0) 13.5 (2.7) −0.40 (0.86) 10 (25.0)
Language 0.02 (0.74) −0.04 (0.84)
Category Fluency (animals) 25.4 (5.8) −0.03 (0.79) 25 (10.5) 24.3 (6.5) −0.11 (0.96) 8 (20.0)
Category Fluency (professions) 19.1 (4.8) 0.07 (0.91) 28 (11.7) 18.2 (4.3) 0.03 (0.94) 6 (15.0)
Information-processing speed 0.02 (0.72) −0.49 (0.93)
Trail Making Test part Ab 30.5 (11.5) 0.19 (0.84) 24 (10.0) 33.9 (12.0) −0.01 (0.85) 6 (15.4)
Stroop Color-Word Test (Card I)b 44.1 (8.7) −0.10 (0.99) 46 (19.3) 48.0 (9.9) −0.50 (1.13) 8 (21.1)
Stroop Color-Word Test (Card II)b 58.9 (12.5) −0.23 (1.10) 53 (22.3) 66.1 (13.9) −0.84 (1.18) 16 (42.1)
Symbol-Digit Substitution Test 57.6 (11.3) 0.05 (0.99) 31 (13.0) 49.5 (10.6) −0.59 (1.10) 11 (27.5)
Executive functions 0.33 (0.68) 0.11 (0.73)
Trail Making Test interference
score (Part B/Part A)b
2.3 (0.7) −0.13 (0.99) 45 (18.8) 2.5 (0.6) −0.38 (0.92) 9 (23.1)
Stroop interference score
(Card III/average Card I and II)b
1.8 (0.3) 0.78 (0.71) 4 (1.7) 1.9 (0.3) 0.61 (0.86) 1 (2.6)
Abbreviations: RAVLT Rey auditory verbal learning test
amean standardized age, sex and education-adjusted normative z-scores (SD) are presented for the domains, mean raw scores (SD), as well as mean z-scores (SD),
and percentage of subjects with a cognitive decrement (z-score < 1.0 SD below the age, sex and education-adjusted normative mean) are presented for the
separate tests. Higher scores represent better cognitive performance, unless otherwise indicated
bhigher scores represent worse cognitive performance
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